Sunshine Biopharma

SBFM

Drug Manufacturers - Specialty & Generic · Healthcare

Price

$1.80

-0.03 (-1.64%)

Market Cap

$901,064

Exchange

NASDAQ Capital Market

Winston Score

Winston is worried

Weak fundamentals across most pillars.

Share count rising — dilution

+317235.1% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 131 (2021) → 416K (2025)

Sunshine Biopharma is a small pharmaceutical company focused on developing and selling cancer-fighting drugs and other medicines. Its main product is Adva-27a, an experimental compound targeting multiple types of cancer, and it also sells generic pharmaceutical products to generate near-term revenue. The company serves patients and healthcare providers, primarily in North America.

Sunshine Biopharma makes money by selling generic drugs while simultaneously spending on research to develop its own proprietary treatments. It is a very small company with a market cap under $100 million, and it operates at a loss, meaning it spends more than it earns right now. The biggest risk the company faces is running out of cash before it can get its experimental cancer drugs approved by regulators — a common and serious challenge for early-stage drug developers.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-9.1% YoY

YoY Growth Rate

Revenue declining

EPS Growth

+43.2% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$604,308/ year

↓ Declining (-35% vs prior year)

1.7% of revenue

Below sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

0.6%ownership

Relatively low insider ownership

Cash Runway

~10 months

$7M cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Short runway — potential dilution ahead through share issuance

Cash watch

Sunshine Biopharma has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

26.0%

Modest — 26.0% gross margin

Operating Margin

-17.3%

Losing money on operations — -17.3%

ROCE

-6.4%

Weak — -6.4% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

-2.0%

Shrinking sales (-2.0% YoY)

EPS YoY

N/A

—

Data not available

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

-19.9%

Burning cash (-19.9%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

0.01

Conservative — low debt load (0.01)

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial